Overall response rate (ORR) as a potential surrogate for progression-free survival (PFS): A meta-analysis of metastatic non-small cell lung cancer (mNSCLC) trials submitted to the U.S. Food and Drug Administration (FDA).
Gideon Michael Blumenthal
No relevant relationships to disclose
Stella Karuri
No relevant relationships to disclose
Sean Khozin
No relevant relationships to disclose
Dickran Kazandjian
No relevant relationships to disclose
Hui Zhang
No relevant relationships to disclose
Lijun Zhang
No relevant relationships to disclose
Shenghui Tang
No relevant relationships to disclose
Rajeshwari Sridhara
No relevant relationships to disclose
Patricia Keegan
No relevant relationships to disclose
Richard Pazdur
No relevant relationships to disclose